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Background/aim: Diabetes mellitus (DM) is one of the most common metabolic diseases seen in the world today. Diabetic neuropathy
(DN) is a chronic complication of the disease that is rarely reported in children, since it has a relatively longer latency period. Our main
objective in this study is to determine the incidence rate of DN in pediatric DM patients and assess the risk factors associated with DN.
Materials and methods: Data from 111 patients from January 2011 to May 2014 were reviewed in a retrospective manner. Nerve
conduction studies were performed as the gold standard in diagnosis.
Results: The incidence rate of symptomatic DN was 13.5% according to our study results. The EMG-diagnosed DN incidence rate
was calculated as 22.5%. Following linear regression analysis, positive correlation was found between diabetes duration, diabetic
ketoacidosis, and DN presence.
Conclusion: Our study results demonstrate the fact that poor metabolic control, especially during early stages of the disease, is a major
risk factor for neuropathy development. Planning prospective studies with long-term evaluations on nerve conduction in children with
DM will be beneficial for this subject.
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1. Introduction
Diabetes mellitus (DM) is a metabolic disorder
characterized by anomalies in carbohydrate metabolism.
Diabetic neuropathy (DN) is an important complication
seen in diabetic patients and is associated with high
morbidity and mortality rates in addition to a significant
decrease in the quality of life of patients. DN shows itself
in heterogeneous clinical manifestations by affecting
different nerves, either proximal or distal nerves or
sensory, motor, or autonomic nerves. The pathophysiology
of DN is multifactorial, i.e. genetic, environmental,
behavioral, metabolic, neurotrophic, and vascular
factors all play a role in disease development (1,2). The
prevalence of DN is reported to be between 28.5% and
50% in various studies. Peripheral neuropathy, especially
as a complication of DM, has been extensively studied
in adult populations. However, peripheral neuropathy is
rarely mentioned in children as a chronic complication
of DM, as this condition has a longer latent period
during its development. Distal symmetric sensorimotor
polyneuropathy is the most commonly diagnosed clinical
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type of DN. Electrophysiological studies in diabetic
patients usually demonstrate nonspecific signs of axonal
degeneration in addition to demyelization along nerve
segments (3).
The pathophysiology behind DN is not clearly
understood except for the marked importance of chronic
hyperglycemia, which is thought to be the main culprit
in neurovascular damage initiation (4–6). However, the
basic pathophysiology of DN is still unknown. Some
authors attributed neuropathy to vascular changes
(7), while others found no relationship between
hyperglycemia and peripheral vascular disease (8). Other
studies suggested that mechanical injury (9) and nerve
entrapment (10) play prominent roles and are aggravated
by vascular factors.
Previous studies usually reported that age, male sex,
disease duration, and glycemic control are all factors
affecting nerve conduction (8,11). For this reason, our
main objective in this study is evaluation of DN incidence
rate in children with type 1 DM and determination of the
associated risk factors.
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2. Materials and methods
2.1. Subject selection
Ethical approval for this study was obtained from the
Ethics Committee of Dr. Behçet Uz Children’s Training
and Research Hospital. A total of 111 patients, comprising
59 (53.2%) boys and 52 (46.8%) girls, were included
in the study. All patients were followed in the Child
Neurology and Endocrinology Clinic with a type 1 DM
diagnosis. Data from electromyography (EMG) studies of
these patients between January 2011 and May 2014 were
reviewed in a retrospective fashion. We did not examine
B12 levels in this patient group.
2.2. Statistical analysis
Patient age, diabetes duration at the time of EMG
implementation, mean HbA1c values, clinical
manifestations, frequency of diabetic ketoacidosis, insulin
dosage at the time of EMG, neurological examination
results, and electrophysiological evaluation results were
all recorded. Statistical analysis was performed using SPSS
10.0 for Windows. EMG was performed using Nihon
Kohden MEB 9400 EMG equipment. Electrophysiological
assessment was done by 2 child neurology specialists in the
Dr. Behçet Uz Children’s Training and Research Hospital’s
Electrophysiology Laboratory.
Under conventional room temperature settings,
sensory and motor nerve conduction studies were
performed for both the lower and upper extremities of
the patients. The protocol included the unilateral (right
side) median, ulnar and sural sensory conductions, and
right-side peroneal and tibial motor conductions. Another
peripheral nerve involvement, detected in more than
two peripheral nerve conduction defects, was used as a
criterion for the diagnosis of polyneuropathy detection.
Descriptive statistics of patients were recorded. In
addition, multiple linear regression analysis was done to
assess the possible correlated factors between neuropathy
symptoms and body mass index (BMI), EMG results, sex,
mean HbA1c, neuropathy period, previous episodes of
diabetic ketoacidosis, and insulin requirements.
3. Results
The male-to-female ratio was 1:1.3. Median age of the
patients was 138 months, with a range from 39 to 227
months. Fifty-two (46.8%) patients were previously
diagnosed with diabetic ketoacidosis, while 48 (43.2%)
patients had classical diabetes symptoms and 10 (9%)
patients were asymptomatic at diagnosis. At the time
of EMG, 79 (71.2%) of the patients had been diagnosed
with DM in the last 5 years, 25 (22.5%) patients had been
diagnosed within 5–10 years, and 7 (6.3%) patients had
been diagnosed more than 10 years previously. Median
height was 146 cm (range: 95–186 cm) while median
weight was 37 (15–90) kg. Median BMI was 17.9 (11.9–

35.1). One hundred (90.1%) patients showed no symptoms
of DN while 11 (9.9%) were symptomatic during EMG
studies. Forty-seven (42.3%) patients had no history of
diabetic ketoacidosis prior to EMG while 53 (47.7%)
patients had one, 6 (5.4%) patients had two, 4 (3.6%)
patients had three, and 1 (0.9%) patient had four previous
diabetic ketoacidosis attacks previously. Twenty-five
(22.5%) patients were using insulin at doses lower than 0.5
IU/kg, 59 (53.2%) patients were using doses between 0.5
and 1 IU/kg, and 27 (14.3%) patients were using 1–2 IU/
kg insulin. Seventeen (15.3%) patients had median HbA1c
levels below 7.5, 25 (22.5%) patients had HbA1c levels
between 7.51 and 9, and 69 (62.2%) patients had HbA1c
levels above 9.
During EMG, 84 (75.7%) of the patients were
unremarkable and 19 (17.1%) patients were diagnosed with
sensorial neuropathy in addition to 3 (2.7%) patients with
motor neuropathy and 5 (4.5%) patients with sensorimotor
neuropathy. The incidence rate of symptomatic DN was
13.5% and the incidence rate of DN diagnosed with EMG
was 22.5%.
Following multiple linear regression analysis that
included EMG results, sex, median HbA1c levels, diabetes
duration, number of prior diabetic ketoacidosis episodes,
daily insulin requirement level, presence of neuropathy
symptoms, and BMI, a positive correlation was found
between DN and diabetes duration (P = 0.002) and between
DN and number of previous diabetic ketoacidosis episodes
(P = 0.03) (Table). No significant positive relationship was
detected for sex, BMI, daily insulin requirement, or DN
symptom presence.
4. Discussion
Epidemiologic and clinical features show substantial
differences among countries and populations in type 1 DM.
The primary goal in type 1 DM management is to prevent
and control micro- and macrovascular complications by
achieving good glycemic control. It has been long known
that there is a positive correlation between diabetes
duration and DN prevalence (5,6). Clinical neuropathy is
rarely diagnosed in pediatric populations, despite the fact
that subclinical neuropathy is quite common, especially
in adolescent patients. Nerve conduction studies are the
Table. Results of multiple linear regression analysis.
Parameter

P

HbA1c level

0.268

Duration of diabetes

0.002

Number of diabetic ketoacidosis

0.037

Symptoms of neuropathy

0.986
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gold standard in the detection of DN on the subclinical
level. Likewise, our study revealed a positive correlation
between diabetes duration and DN (P = 0.002)
Şimşek et al.’s study reported that DN patients tended
to be significantly older than the control group (patients
without DN). Mean diabetes duration was significantly
longer in patients with DN in comparison with controls,
as well. There was no significant difference detected in
mean HbA1c levels in the past year in DN patients when
compared to controls (8). Their results are in accordance
with our study findings, which showed no relations
between HbA1c levels and DN.
The incidence rate of symptomatic DN was 13.5% in
our study. The same rate for DN diagnosed by EMG was
calculated as 22.5%. Höllner et al. reported that incidence
as 15% in symptomatic DN cases and 38% in DN cases
diagnosed by EMG. Their conclusion was that in type 1
DM seen in children and adolescents, diabetic neuropathy
has a higher prevalence rate; however, the majority of
cases remain subclinical. For this reason, routine nerve
conduction velocity (NCV) assessment for DN seems to be
beneficial in those patient groups (4). In the EURODIAB
study, DN prevalence as diagnosed by electrophysiological
studies was 23.5% in 276 children with type 1 DM (5).
Our study results seem to be compatible with the results
of previously published studies found in the literature.
Therefore, we can argue that it is crucial to screen children
with type 1 DM for DN, even if they are asymptomatic.
In our study, DN was diagnosed in 3 cases a month
after type 1 DM diagnosis was made. Marcus et al. found
a significant correlation between NCV and duration of
the disease; however, there were a few exceptions. A male
patient with a disease duration of 15.5 years had normal
NCV results despite showing signs of clinical neuropathy.
In addition, two other patients, one with absent reflexes
whose DM diagnosis was relatively fresh and one patient
diagnosed with diabetes 2 months earlier without
neuropathic findings, showed low NCV results. In the
former case, one can explain that that decrease in NCV
is caused by acute metabolic changes, as suggested by
Gregersen; however, in the other patient, one would expect
these changes to have returned to the normal range within
2 months (12,13). For this reason, more extensive studies
with larger series are necessary on this subject.
Hansen et al. proved that high blood glucose levels
for several years is the major factor in the development
and progression of microvascular complications related
with type 1 DM. Controlling mean blood glucose levels
significantly reduces the risk of diabetic microvascular
complications. A curve-linear relationship is present
between HbA1c levels and DN progression (7). In a more
recent study, early defects in NCV could be used as a
predictive factor in DN development. However, HbA1c
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still remains the strongest predictor during the early years
of the disease (10). Gregersen and Chantraine also found
greater NCV reduction in their younger patients and
reported that the change was bigger during the first year
of the disease (14,15).
Children with type 1 DM frequently have nerve
conduction anomalies without showing any clinical
neuropathy at the time of their diagnosis. The frequency
of any anomalies attributed to nerve conduction increases
over a 5-year follow-up period. Moreover, duration of
the disease and poor glycemic control also are proven to
be important risk factors over 5 years as related to the
development of subclinical neuropathy (14).
We could not find a correlation between DN incidence
rates and mean HbA1c levels. Another multicentric
study done in Turkey on pediatric DM patients also did
not report a direct relationship between type 1 DM and
HbA1c or the incidence rate of neuropathy (8). According
to the results of the mentioned study, higher HbA1c levels
might increase the incidence of neuropathy if it goes on
for a long time.
The EURODIAB study results suggest that,
following adjustment for other risk factors and diabetic
complications, duration of diabetes, current HbA1c values,
changes in HbA1c values during the follow-up period,
BMI, and smoking remain independently associated with
neuropathy incidence rates. This prospective study also
indicated that, apart from glycemic control, the incidence
of neuropathy is partially associated with relatively
modifiable cardiovascular risk factors that include raised
triglyceride levels, BMI, smoking, and hypertension
(5). Five years later, in addition to diabetes duration and
HbA1c, nephropathy, retinopathy, or a clinical diagnosis
of neuropathy was also associated with low NCV and
response amplitudes. On the other hand, that study
did not find any association with high blood pressure,
lipid levels, BMI, waist-to-hip ratio, smoking, or alcohol
consumption (11). In the Rochester Diabetic Neuropathy
Study, the major risk factors for DN were determined
to be poorly controlled diabetes; duration of diabetes,
smoking, hypertension, and dyslipidemia were also listed
as other risk factors (9). All those mentioned studies were
performed with adult patients in a prospective fashion.
We were not able to determine serum lipid levels in our
patients because of our study’s retrospective status.
We managed to find a positive correlation between
DN and diabetic ketoacidosis, which signifies poor
management of DM. This finding is compatible with
the findings of Marcus et al. (12), Gregersen (13), and
Gamstrop et al. (16). Diabetic control assessment is
arbitrary, regardless of which criteria are used. Very few
if any children can achieve “perfect control”, i.e. return
to a normal metabolic state. In diabetes, the general
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breakdown of normal metabolism might play a major
part in DN, and in addition acute changes in motor nerve
conduction velocity (MNCV) with use or withdrawal of
insulin support this suggestion, as seen in Gregersen’s study
(13). Moreover, such a breakdown can be used to explain
Ellenberg’s (17) group of patients and our one newly
diagnosed patient with very low MNCV in addition to
MNCV levels lower than normal ranges in most diabetics.
However, it is not able to explain the relatively normal
MNCV in some patients with longer diabetes durations.
Hyllienmark et al. reported that nerve dysfunction
seen during early periods of the disease is a predictor
of clinical neuropathy that might develop several years
later. Decreases in baseline peroneal NCV, median NCV,
and sural sensory nerve action potential were associated
with a significantly increased risk of developing clinical
neuropathy in an average of 13 years following initial
electrophysiological examination. Forward logistic
regression model analysis showed a positive predictive
value of an early decrease in peroneal NCV, even when
long-term HbA1c levels were accounted for. This unique
result once more emphasizes the importance of the role
of early NCV measurements in young diabetic patients.
The strongest predictor for the development of a clinical
neuropathy was poor metabolic control during early
periods of the disease (i.e. up to baseline examination)
(10).
Samahy et al. suggested that patients with poor glycemic
control had longer disease durations, higher diabetic
ketoacidosis frequency, and diabetic microvascular

complications. These results indicated that, although the
majority of patients were on intensive insulin therapy,
poor glycemic control was relatively common and diabetic
microvascular complications were observed (12).
The main factor that determined the severity of DN
course was the age of DM onset. This shows the significance
of more accurate control since the DN development risk is
higher in children with DM onset at age 12–13. During
early stages of DM, conductivity through peripheral
nerves correlated with glycosylated hemoglobin and with
the frequency of hypoglycemic states (18).
All of our findings suggest that poor metabolic control,
especially during early periods of the disease, is a major
risk factor for neuropathy development, independently of
whether patients are treated with conventional or intensive
therapy for the condition. Contrary to intensive therapy
from disease onset with reasonably good metabolic
control, clinical neuropathy was still seen in 15% of the
patients with type 1 DM following an average of 20 years.
In summary, early detection of children and
adolescents with suspected NCV anomalies is essential to
plan all appropriate measures to be taken for preventing
DN development. It is especially important to perform
nerve conduction studies for patients who have had long
diabetes durations and previous diabetic ketoacidosis
episodes. We strongly believe that new studies, especially
prospective models with long-term evaluations, would be
beneficial in understanding NCV in children with type 1
DM.
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